KRAS and cancer: Given that BAD is a vital downstream mediator of RAS effector pathways mediating cancer cell survival and apoptosis [25], targeting its phosphorylation may be and is demonstrated herein, to be advantageous for the treatment of KRAS-mutant PDAC.